Wani ɗan baya: a ƙarshen 2020, Isra'ila na fuskantar tudun ruwa mara komai. Babu wani matakin tsauraran matakan da Isra'ila ta dauka kan COVID - kulle-kulle, nisantar da jama'a, rufe makarantu da yunƙurin katse jerin cututtukan ta hanyar keɓewa - da ya yi nasarar hana yaduwar cutar.
Bugu da kari, firaministan kasar na lokacin Benjamin Netanyahu ya fuskanci barazanar ruguza gwamnatinsa da kuma maye gurbin shugabancinsa a zaben. Duk wannan an rufe shi da tuhumar da ake yi masa. Netanyahu ya yanke shawarar yin caca kan allurar Pfizer a matsayin dabarar da za ta iya ba shi damar magance matsalar COVID, tare da ƙarin fa'idar fa'idar siyasa.
Ta wannan hanyar, don musanya gata ta zama ƙasa ta farko a duniya da ta fara fitar da alluran rigakafin a tsakanin al'ummarta, Isra'ila ta kulla yarjejeniyoyin biyu da Pfizer: yarjejeniyar samarwa da samarwa da ba a bayyana a fili ba; kuma"Yarjejeniyar Haɗin Kan Shaida ta Gaskiya ta Duniya,” wanda aka tattauna a wannan talifin.
An rattaba hannu kan "Yarjejeniyar Haɗin Kan Shaida ta Gaskiya ta Duniya" a ranar 6 ga Janairu, 2021. Manufar da aka bayyana shi ne tattarawa da kuma nazarin bayanan cututtukan da suka taso daga allurar rigakafin al'umma a Isra'ila, da kuma sanin ko za a sami rigakafin garken garken a sakamakon rigakafin. A cikin tsarin wannan yarjejeniya, an bayyana matakan sakamakon bincike.
Matakan da aka samu ba su haɗa da aminci ba. Duk matakan sakamako da aka bayyana a fili a cikin yarjejeniyar sun kasance sakamakon inganci, kamar adadin waɗanda suka kamu da COVID, adadin asibitocin COVID, da mutuwa daga COVID, ko fihirisa kan saurin fitar da allurar rigakafin a Isra'ila, kamar adadin alurar riga kafi ta shekaru da halayen alƙaluma.
Babu ɗaya daga cikin matakan sakamakon da aka amince da shi a sarari da ya kasance sakamakon aminci, kamar yawan mace-mace, asibiti daga kowane dalili ko sanannun illolin alluran rigakafi, duk abin da ya kasance.
Menene ya ƙunshi " bala'i?" - Yarjejeniyar ta hada da sanarwar, bisa ga abin da bangarorin biyu suka amince da cewa nasarar hadin gwiwar ya dogara da adadin da adadin allurar rigakafin ga al'ummar Isra'ila. Ma'aikatar lafiya ta Isra'ila ta yi alƙawarin cewa za a gudanar da rarraba, turawa, da kuma samar da rigakafin ga jama'a cikin lokaci.
An amince da wannan ba tare da wani sharadi ba game da amincin rigakafin, in ban da “ bala’i” wanda zai kai ga cire allurar daga kantuna. Ba a fayyace a cikin yarjejeniyar ba, abin da ya kunshi bala’i, ko wane bangare ne zai iya shelanta wani bala’i da kuma matakan da ya kamata a dauka domin gano wani bala’i kafin ko kuma a farkon afkuwar lamarin.
Pfizer zai ba da ƙwararru da ƙwarewa – Yarjejeniyar ta bayyana cewa Pfizer zai yi aiki tare da ma’aikatar lafiya ta Isra’ila ta hanyar samar da, bisa ga ra’ayin Pfizer, kwararru a fannonin: cututtuka masu yaduwa da na numfashi, alluran rigakafi, cututtukan cututtuka, yin samfurin lissafi, nazarin bayanai da lafiyar jama’a. Bangarorin sun amince su baiwa juna takardu da shirye-shiryen kwamfuta don tantance bayanai.
A wasu kalmomi, yarjejeniyar ta bayyana cewa aikin Pfizer ba wai kawai ya kai ga samar da alluran rigakafi da kafa manufofin bincike ba, har ma da samar da kwararru a fannin nazarin bayanai, da kuma shirye-shiryen nazarin bayanai na kwamfuta. Don haka, Ma'aikatar Lafiya ta Isra'ila ta yi watsi da 'yancin kai na kimiyya, ba kawai wajen tantance manufofin bincike ba, har ma da yin binciken.
Sarrafa wallafe-wallafe - Wani sashe a cikin yarjejeniyar ya tattauna wallafe-wallafe a sakamakon binciken haɗin gwiwar. Bangarorin sun amince su buga tare a cikin wallafe-wallafen kimiyya da na likitanci, yayin da suke nuna gudummawar kowannensu. Duk da haka - kuma wannan babban "duk da haka" - idan ɗayan jam'iyyun sun yanke shawarar bugawa daban, kowanne ɗayan jam'iyyun yana da hakkin ya hana ɗayan jam'iyyar ambaton jam'iyyar farko a cikin littafin.
A takaice dai, Pfizer yana da iko a karkashin yarjejeniyar don barin duk wani batun gudummawar da yake bayarwa ga binciken, don haka ba a ambaton sa hannu wajen kafa manufofin bincike, hanyoyin ko ma a rubuta sakamakon binciken kwata-kwata.
Don haka, ana iya siffanta binciken a matsayin mai zaman kansa daga Pfizer, kodayake ba lallai bane haka. Bugu da kari, idan ko wanne bangare na son buga shi ba tare da daya bangaren ba, to hakki ne na jam’iyyar da ke son bugawa ta mika littafin don dubawa da kuma jin ra’ayin daya bangaren (an rage lokacin da aka ware don yin bitar ba mu san tsawon lokacin ba). Wannan shine yadda jam'iyyar da ba ta da sha'awar wallafar za ta iya jinkirta shi - wanda zai iya sa littafin ya zama mara ma'ana a cikin wani abu mai ƙarfi kamar COVID. A takaice dai, yarjejeniyar tana ba Pfizer babban iko akan abun ciki da lokacin wallafe-wallafe.
Haƙƙin Pfizer don amfani da bayanan da aka tattara - A karkashin yarjejeniyar, Ma'aikatar Lafiya ta ba Pfizer 'yancin yin amfani da bayanan da aka tattara a matsayin wani ɓangare na haɗin gwiwar don dalilai kamar bincike da haɓakawa, ƙaddamarwa ga hukumomin da suka dace, wallafa kimiyya, da sauran manufofin kasuwanci.
Sassan da aka gyara - Ya kamata a lura cewa an sake gyara dukkan sassan da ke cikin nau'in yarjejeniyar da aka samu a bainar jama'a, kamar yadda duka jimloli ko lambobi masu mahimmanci daga wasu sassan suke. Sashi na 6, wanda ke magana game da ramuwa da iyakancewar lalacewa da abin alhaki, an sake gyara gabaɗayan sa.
Haka yake ga Sashe na 10.10 wanda ke magana da warware takaddama. A cikin Sashe na 3, wanda ke ba da cikakken bayani game da gudummawar kowane bangare ga haɗin gwiwar kuma don haka shine tushen yarjejeniyar, akwai wata jumla da aka sake gyarawa a wani wuri mai cike da damuwa: daidai bayan amincewar juna ta Pfizer da Ma'aikatar Lafiya cewa "yiwuwa da nasarar aikin ya dogara da ƙimar da girman allurar rigakafi a cikin Isra'ila," kuma daidai a gaban ma'aikatar lafiya don tabbatar da duk abin da zai haifar da cikas ga ma'aikatar lafiya. rarrabawa, turawa da amfani” maganin.
Suna da lakabin Pfizer wanda ya rattaba hannu kan yarjejeniyar, da kuma sunan wakilinsu don warware takaddama, an kuma sake sauya suna. Abin da ya sa wannan ya zama dole abin mamaki.
Me yasa yarjejeniyar da Pfizer ke da mahimmanci haka? Domin ita ce ke mayar da jihar daga wata hukuma mai cikakken iko ta zama wakiliyar wani kamfanin harhada magunguna da ke neman yin aiki a yankinta. Matsayin da jihar ke takawa ita ce ta kare lafiyar al'ummarta da mazaunanta.
Sakamakon haka, yana sanya aminci, inganci da buƙatun inganci akan kamfanonin harhada magunguna, kuma yana aiki da tsarin tsari tare da ikon doka don sanin ko magungunan sun cika waɗannan buƙatun ko a'a. Matsayin da kamfanin kera magunguna shine gwada inganci da aminci da tabbatar da inganci, zuwa cikakkiyar gamsuwar jihar.
Wanda ke kasuwa da rarraba magungunan ba shakka kamfanin magunguna ne ba jiha ba. Wannan ba haka ba ne a karkashin yarjejeniyar da Pfizer, wanda Ma'aikatar Lafiya ta dauki wasu ayyuka na masu kulawa, kuma a gaskiya ma ta sanya kanta cikin rikici tare da nata aikin a matsayin mai kulawa: ya biyo bayan yarjejeniyar da Ma'aikatar Lafiya ta juya zuwa: (1) mai rarraba alluran rigakafi da kasuwa ga jama'a; (2) dan kwangilar bincike da tattara bayanai kan sakamakon da nufin kimanta ingancin alluran rigakafi kadai, ba kare lafiyarsu ba; (3) "Mawallafin" labaran kimiyya - yana buƙatar amincewar Pfizer yadda ya kamata - a ƙarƙashin tsarin ilimi na hukumomin kiwon lafiya (kamar manyan kudaden kiwon lafiya ko kuma Ma'aikatar Lafiya da kanta).
Ma'aikatar Lafiya ta yi bincike game da allurar, wanda manyan jami'ai suka rubuta tare kuma aka buga a cikin mashahuri New England Journal of Medicine (NEJM), Da Lancet da kuma Circulation, galibi game da ingantaccen sakamakon bincike da aka ayyana a cikin yarjejeniyar haɗin gwiwa. A'a Kadan fiye da 10 articles gwada kawai inganci sakamako, daidai as bayyane tsare a cikin yarjejeniya. Biyu articles (kuma a wasika zuwa ga editan) yayi nazarin sakamakon aminci guda ɗaya - myocarditis - kuma ya kammala cewa yana bayyana sau da yawa kuma yawanci yana da laushi.
Babu ɗaya daga cikin labaran da ke bayar da rahoto kan manyan sakamako guda biyu da ake buƙata don ingantaccen ƙima na fa'idar rigakafin ga haɗarin haɗari: gabaɗayan mace-mace ga kowane dalili da kuma asibiti ga kowane dalili, idan aka kwatanta da ingantacciyar hanyar ƙididdiga tsakanin waɗanda aka yi wa alurar riga kafi da waɗanda ba a yi musu allurar ba.
Me yasa jami'an ma'aikatar lafiya suka shiga wannan yarjejeniya? Me ya sa ba su kula da matsayinsu na masu gudanarwa ba, kuma me ya sa suka ba da kansu don yin hidima a matsayin reshen tallace-tallace, rarrabawa, bincike da wallafawa na Pfizer? Da alama akwai yuwuwar matsin lamba daga Netanyahu da ofishinsa ya ba da gudummawa ga lamarin. Amma kusurwar sirri, da yuwuwar rikice-rikicen sha'awar da zai iya haifarwa, ba za a iya watsi da su ba: martabar ilimi da labarai da yawa da aka buga a ciki. NEJM da Lancet na iya canza rayuwa ta fuskar martabar ilimi da haɓakawa.
To, menene ainihin abin da muke da shi a nan? Yarjejeniyar haɗin gwiwar bincike tsakanin Ma'aikatar Lafiya da Pfizer tana nuna ra'ayi da aka riga aka tsara bisa ga abin da maganin ke da lafiya don amfani kuma duk abin da ya rage don bincike shine alamomi daban-daban waɗanda ya kamata su nuna ingancinsa.
Wannan shi ne duk da cewa a lokacin da aka shiga yarjejeniyar an kafa kima lafiya na rigakafin Pfizer akan gwajin bazuwar wanda ya yi ƙanƙanta da gajere don ba da damar isassun siffa na mahimman abubuwan aminci, kamar mutuwar gabaɗaya daga kowane dalili.
Yin watsi da wannan ra'ayi na farko ya zama kusan ba zai yiwu ba da zarar an rattaba hannu kan yarjejeniyar, saboda rikice-rikice, ba kawai tsakanin manufofin siyasa na Netanyahu da muradun kasuwancin Pfizer ba, har ma da yuwuwar a tsakanin su da martabar ilimi na manyan jami'an ma'aikatar lafiya. Da Isra'ila ta yi kyau da ta daina shiga yarjejeniyar.
Ta haka ne Isra’ila za ta iya fitar da shirinta na allurar rigakafin a cikin ma’auni a tsakanin al’ummomin da ke cikin hadarin, ba tare da yin gaggawar yin hakan ba sakamakon wani aiki na kwangila, kuma ba tare da tilasta mata a aikace ta hanyar Green Pass ga daukacin jama’a ba, da kuma kan yara, musamman.
-
Dokta Guy Shinar masanin kimiyya ne wanda ke da fiye da shekaru 20 na gwaninta a cikin bincike da ci gaba da na'urorin likitanci, gwaje-gwaje na asibiti da kuma al'amurran da suka shafi. Shi mai ƙirƙira ne, mai haɗin gwiwa kuma babban jami'in fasaha a cikin kamfanoni da yawa na farawa. Yana da digirin digirgir daga Cibiyar Kimiyya ta Weizmann, inda ya kware a fannin ilimin halittu da ka'idar hanyar sadarwa ta sinadarai.
Duba dukkan posts
